Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TECH | BIO-TECHNE Corp | 2026-09-17 14:59:55 | 72.42 | 0.1 | 0.14 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TECH | 0000842023 | BIO-TECHNE Corp | US09073M1045 | 54930073RLKQ51TILZ35 | 411427402 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 0630 | MN | 614 MCKINLEY PLACE NE | MINNEAPOLIS | MN | 55413 | UNITED STATES | US | 612-379-8854 | 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN, 55413 | 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN | TECHNE CORP /MN/ | Biotechnology | 1976 | Kim Kelderman | 3,100 | https://www.bio-techne.com | 9,100,000,000 | 156,095,113 | 156,818,238 | Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets. | 2026-09-17 18:42:50 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2026 | 9,100,000,000 | -2,300,000,000 | -20.1754 | 156,818,238 | 1,268,651 | 0.8156 |
| 2025 | 11,400,000,000 | -700,000,000 | -5.7851 | 155,549,587 | -3,050,821 | -1.9236 |
| 2024 | 12,100,000,000 | -900,000,000 | -6.9231 | 158,600,408 | 426,096 | 0.2694 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| William Geist | President | 2025 | 573,200 | 0 | 1,206,585 | 748,026 | 18,040 | 3,139,299 |
| Matthew Mcmanus | President | 2025 | 572,000 | 0 | 1,213,200 | 444,787 | 19,937 | 2,846,619 |
| Kim Kelderman | President, CEO | 2025 | 936,000 | 0 | 3,929,942 | 1,318,917 | 33,473 | 8,151,181 |
| James Hippel | CFO, Executive Vice President | 2025 | 723,000 | 0 | 4,453,020 | 926,163 | 17,926 | 7,027,382 |
| Shane Bohnen | General Counsel, Senior Vice President | 2025 | 431,000 | 0 | 767,575 | 386,478 | 18,183 | 1,980,732 |
| Fiscal Year | Employee Count |
|---|---|
| 2026 | 3,000 |
| 2025 | 3,100 |
| 2024 | 3,100 |
| Fiscal Year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Revenue | 1,215,039,000 | 1,219,635,000 | 1,159,060,000 |
| Cost Of Revenue | 415,968,000 | 429,363,000 | 389,335,000 |
| Gross Profit | 799,071,000 | 790,272,000 | 769,725,000 |
| Research And Development Expenses | 94,766,000 | 99,496,000 | 96,664,000 |
| General And Administrative Expenses | 452,415,000 | 588,521,000 | 466,375,000 |
| Operating Expenses | 547,181,000 | 688,017,000 | 563,039,000 |
| Operating Income | 251,890,000 | 102,255,000 | 206,686,000 |
| Net Income | 181,862,000 | 73,400,000 | 168,105,000 |
| Earnings Per Share Basic | 1.17 | 0.47 | 1.07 |
| Earnings Per Share Diluted | 1.16 | 0.46 | 1.05 |
| Weighted Average Shares Outstanding Basic | 155,963,000 | 157,521,000 | 157,708,000 |
| Weighted Average Shares Outstanding Diluted | 157,009,000 | 159,717,000 | 160,774,000 |
| Fiscal Year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Cash And Cash Equivalents | 264,712,000 | 162,186,000 | 151,791,000 |
| Marketable Securities Current | — | — | 1,072,000 |
| Accounts Receivable | 216,585,000 | 206,876,000 | 241,394,000 |
| Inventories | 195,744,000 | 189,446,000 | 179,731,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 67,360,000 | 37,460,000 | 33,658,000 |
| Total Assets Current | 744,401,000 | 608,300,000 | 617,419,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 231,836,000 | 245,719,000 | 251,154,000 |
| Other Assets Non Current | 264,336,000 | 273,609,000 | 264,265,000 |
| Total Assets Non Current | 231,836,000 | 245,719,000 | 251,154,000 |
| Total Assets | 2,586,726,000 | 2,557,868,000 | 2,703,867,000 |
| Accounts Payable | 26,699,000 | 25,311,000 | 37,968,000 |
| Deferred Revenue | 36,072,000 | 32,571,000 | 27,930,000 |
| Short Term Debt | — | 346,000,000 | — |
| Other Liabilities Current | 4,025,000 | 1,645,000 | 2,151,000 |
| Total Liabilities Current | 163,700,000 | 175,849,000 | 159,379,000 |
| Long Term Debt | 200,000,000 | 346,000,000 | 319,000,000 |
| Other Liabilities Non Current | 21,345,000 | 27,082,000 | 13,157,000 |
| Total Liabilities Non Current | 314,805,000 | 463,211,000 | 475,638,000 |
| Total Liabilities | 478,505,000 | 639,060,000 | 635,017,000 |
| Common Stock | 1,561,000 | 1,550,000 | 1,582,000 |
| Retained Earnings | 1,144,188,000 | 1,066,049,000 | 1,325,247,000 |
| Accumulated Other Comprehensive Income | -70,580,000 | -59,880,000 | -78,316,000 |
| Total Shareholders Equity | 2,108,221,000 | 1,918,808,000 | 2,068,850,000 |
| Fiscal Year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Depreciation And Amortization | 97,359,000 | 109,903,000 | 111,711,000 |
| Share Based Compensation Expense | 41,365,000 | 40,833,000 | 38,042,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 10,793,000 | -34,132,000 | 20,533,000 |
| Change In Inventories | 8,232,000 | 18,144,000 | 14,215,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 3,180,000 | -13,954,000 | 25,769,000 |
| Change In Other Liabilities | -7,671,000 | 15,408,000 | 12,618,000 |
| Cash From Operating Activities | 292,073,000 | 287,556,000 | 298,981,000 |
| Purchases Of Marketable Securities | — | — | 5,526,000 |
| Sales Of Marketable Securities | — | 1,085,000 | 28,083,000 |
| Acquisition Of Property Plant And Equipment | 28,850,000 | 31,006,000 | 62,877,000 |
| Acquisition Of Business | — | — | 169,707,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -18,190,000 | -35,183,000 | -203,030,000 |
| Tax Withholding For Share Based Compensation | 12,141,000 | 6,522,000 | 21,872,000 |
| Payments Of Dividends | 49,916,000 | 50,391,000 | 50,419,000 |
| Issuance Of Common Stock | 3,910,000 | 4,470,000 | 39,893,000 |
| Repurchase Of Common Stock | 41,675,000 | 275,731,000 | 80,042,000 |
| Issuance Of Long Term Debt | — | 104,000,000 | 225,000,000 |
| Repayment Of Long Term Debt | 146,000,000 | 77,000,000 | 256,000,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -169,114,000 | -253,905,000 | -122,398,000 |
| Change In Cash | 102,526,000 | 10,395,000 | -28,780,000 |
| Cash At End Of Period | 264,712,000 | 162,186,000 | 151,791,000 |
| Income Taxes Paid | 64,149,000 | 74,357,000 | 65,254,000 |
| Interest Paid | 14,395,000 | 18,955,000 | 14,502,000 |
| Fiscal Year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Earnings Per Share | 1.17 | 0.47 | 1.07 |
| Price To Earnings Ratio | 60.3846 | 109.4681 | 66.9252 |
| Earnings Growth Rate | 148.9362 | -56.0748 | -40.884 |
| Price Earnings To Growth Ratio | 0.4054 | -1.9522 | -1.637 |
| Book Value Per Share | 13.5174 | 12.1813 | 13.1182 |
| Price To Book Ratio | 5.2266 | 4.2237 | 5.4588 |
| Ebitda | 353,000,000 | 266,169,000 | 360,806,000 |
| Enterprise Value | 10,954,073,950 | 8,634,269,450 | 11,460,678,880 |
| Dividend Yield | 0.0045 | 0.0062 | 0.0045 |
| Dividend Payout Ratio | 0.2745 | 0.6865 | 0.2999 |
| Debt To Equity Ratio | 0.0949 | 0.3606 | 0.1542 |
| Capital Expenditures | 83,476,000 | 104,468,000 | 136,665,000 |
| Free Cash Flow | 208,597,000 | 183,088,000 | 162,316,000 |
| Return On Equity | 0.0863 | 0.0383 | 0.0813 |
| One Year Beta | 1.0311 | 1.1714 | 1.0614 |
| Three Year Beta | 1.1177 | 1.1387 | 1.1445 |
| Five Year Beta | 1.1389 | 1.1512 | 0.9214 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Crouse Steven C. | President - Diag & Spatial Bi | 2026-08-17 | 8,702 | A | 8,702 |
| Crouse Steven C. | President - Diag & Spatial Bi | 2026-08-17 | 14,140 | A | 14,140 |
| Geist William | PRESIDENT, PROTEIN SCIENCES | 2026-08-17 | 14,762 | A | 14,762 |
| Geist William | PRESIDENT, PROTEIN SCIENCES | 2026-08-17 | 23,985 | A | 23,985 |
| Herr Amy E. | Director | 2026-08-17 | 1,381 | A | 1,381 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas R Tillis | Senator | 2015-02-26 | Sale (Full) | 2015-02-13 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| April McClain Delaney | 2026-05-06 | MD06 | Sale | 2026-04-08 | Child | $1,001 - $15,000 |
| April McClain Delaney | 2026-04-06 | MD06 | Sale (Partial) | 2026-03-26 | Child | $1,001 - $15,000 |
| April McClain Delaney | 2026-03-10 | MD06 | Sale (Partial) | 2026-02-24 | Child | $1,001 - $15,000 |
| April McClain Delaney | 2026-02-02 | MD06 | Sale (Partial) | 2026-01-28 | Child | $1,001 - $15,000 |
| April McClain Delaney | 2026-01-05 | MD06 | Purchase | 2025-12-02 | Child | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Assenagon Asset Management S.A. | 2026-06-30 | 210,890 | 2,985 | 70.6499 |
| MERCER GLOBAL ADVISORS INC /ADV | 2026-06-30 | 508,700 | 7,200 | 70.6528 |
| Mint Tower Capital Management B.V. | 2026-06-30 | 379,000 | 5,361 | 70.6958 |
| Rakuten Investment Management, Inc. | 2026-06-30 | 1,176,940 | 16,600 | 70.9 |
| JONES FINANCIAL COMPANIES LLLP | 2026-06-30 | 56,587,061 | 797,001 | 71.0 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| MADISON FUNDS | 2026-07-31 | Mid Cap Fund Class I | MDCIX | 484,784 | 34,948,078.56 | 2.0319 |
| MADISON FUNDS | 2026-07-31 | Mid Cap Fund Class R6 | MMCRX | 484,784 | 34,948,078.56 | 2.0319 |
| MADISON FUNDS | 2026-07-31 | Mid Cap Fund Class Y | GTSGX | 484,784 | 34,948,078.56 | 2.0319 |
| MADISON FUNDS | 2026-07-31 | Mid Cap Fund Class A | merax | 484,784 | 34,948,078.56 | 2.0319 |
| Investment Managers Series Trust III | 2026-07-31 | Class A Shares | CSQAX | 56,852 | 4,098,460.68 | 2.0614 |